Docetaxel rechallenge was associated with longer OS and time to subsequent treatment or death compared with cabazitaxel for patinets with chemonaïve mCRPC.

The ARASAFE study showed that a 50 mg/m2 biweekly docetaxel regimen reduced severe side effects compared to the standard 75 mg/m2 triweekly regimen in mHSPC patients. The experimental regimen resulted ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

Detailed price information for Bayer Aktienges ADR (BAYRY) from The Globe and Mail including charting and trades.

Pertuzumab Retreatment for Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced/Metastatic Breast Cancer (PRECIOUS Study): Final Overall Survival Analysis The standard of care for ...